Trials / Unknown
UnknownNCT04665986
Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer
A Study to Evaluate Navelbine in Combination With Trastuzumab Plus Pertuzumab in Patients With HER2 Positive Early Stage or Locally Advanced Breast Cancer in Neoadjuvant Treatment
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind multicenter Phase III study for evaluating the efficacy of neoadjuvant Navelbine plus trastuzumab and Pertuzumab versus Docetaxel plus trastuzumab and Pertuzumab given as neoadjuvant treatment in HER2 positive early-stage or locally advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Navelbine | Navelbine 25mg/m2 on day 1 and 8, every 3 weeks |
| DRUG | Docetaxel | Docetaxel 90mg/m2 on day 1, every 3 weeks |
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2022-02-28
- Completion
- 2023-02-28
- First posted
- 2020-12-14
- Last updated
- 2020-12-14
Source: ClinicalTrials.gov record NCT04665986. Inclusion in this directory is not an endorsement.